Tesamorelin ���景与作用机制 — Complete Guide

By Editorial Desk · published 2026-03-22 · last reviewed 2026-04-29 · Guide

The short version of Visceral adipose tissue fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-04-29. Anything still debated is marked as such rather than presented as settled.

tesamorelin 背景与作用机制

作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。

研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。

Tesamorelin Background and Mechanism

A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.

Tesamorelin at a glance

Background and Clinical Development

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Related pages on this site

• Tracked casebook
• Tracked summary
• Efficient playbook
• Sustainable analysis
• Modular dataset
• Automated handbook
• Smart reference
• Modular dataset

Identity and Development Background

Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.

Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.

Background and Clinical Profile

Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.

After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.

Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.

Notes from published material

Plants could grow greenhouses... just as turtles grow shells and polar bears grow fur and polyps build coral reefs in tropical seas. These plants could keep warm by the light from a distant Sun and conserve the oxygen that they produce by photosynthesis. The greenhouse would consist of a thick skin providing thermal insulation, with small transparent windows to admit sunlight. Outside the skin would be an array of simple lenses, focusing sunlight through the windows into the interior... Groups of greenhouses could grow together to form extended habitats for other species of plants and animals.

=== RNP-MaP site identification === RNP-MaP sites are defined as protein bound nucleotides. SDA and UV treated and UV only treated sample sequence reads are aligned and mutations are counted using ShapeMapper2 software. The SDA or RNP-MaP reactivity for a nucleotide is the ratio of the crosslinked (SDA and UV treated) mutational frequency to the un-crosslinked (UV only) mutation frequency. Using differential mutational signatures, RNP-MaP sites are identified based on universal normalization factors and thresholds on each RNA nucleotide (U, A, C, and G) derived from analysis of ribonucleoproteins of known structure. A nucleotide is identified as a RNP-MaP site if it passes three filters:

Douglas Carlyle Cameron (born March 22, 1957) is an American engineer, inventor, and investor. He is a senior managing director for the U.S.-China Green Fund. He is on the board of the Foundation for Food and Agriculture Research (FFAR) and is a technical and business advisor to organizations including the VTT (Finland), and the Center for Bioenergy Innovation (USA).

== Processing == PVDF may be synthesized from the gaseous vinylidene fluoride (VDF) monomer by a free-radical (or controlled-radical) polymerization process. This may be followed by processes such as melt casting, or processing from a solution (e.g. solution casting, spin coating, and film casting). Langmuir–Blodgett films have also been made. In the case of solution-based processing, typical solvents used include dimethylformamide and the more volatile butanone. In aqueous emulsion polymerization, the fluorosurfactant perfluorononanoic acid is used in anion form as a processing aid by solubilizing monomers. Compared to other fluoropolymers, it has an easier melt process because of its relatively low melting point of around 177 °C. Processed materials are typically in the non-piezoelectric alpha phase. The material must either be stretched or annealed to obtain the piezoelectric beta phase. The exception to this is for PVDF thin films (thickness in the order of micrometres). Residual stresses between thin films and the substrates on which they are processed are great enough to cause the beta phase to form. In order to obtain a piezoelectric response, the material must first be poled in a large electric field. Poling of the material typically requires an external field of above 30 megavolts per metre (MV/m). Thick films (typically >100 μm) must be heated during the poling process in order to achieve a large piezoelectric response. Thick films are usually heated to 70–100 °C during the poling process.

For voluntary and charitable services to the My Name'5 Doddie Foundation. Helen Ruth Waite. Deputy Director, Family Support, Department for Education. For services to Education. Professor Mark Watson-Gandy. Chair, Biometrics and Forensics Ethics Group. For Public and Voluntary Services. Dr. David Clark Watt. Chair, Fife College. For services to the Economy, to Sport and to Education. Lieutenant Colonel (Rtd) David Ian Whimpenny. Lately Board Trustee, The Royal British Legion. For Voluntary Service. Stephen John Whitton. Head, Border Force Maritime Command, Home Office. For services to Maritime Border Security. Professor Mark Harvey Wilcox. Lately National Clinical Director for Infection Prevention and Control, NHS England and Chair, SAGE Sub-Committee on Hospital Onset Covid Infection. For services to Healthcare, particularly during Covid-19. Howard Wilkinson. Chairman, League Managers Association. For services to Association Football and to Charity. Yvonne Marie Wilks-O'Grady. Philanthropist and Co-Founder, Roots Magazine. For services to Media, to Publishing and to Charity. Professor Bryan Williams. Chair of Medicine, University College London and lately Director of Research, University College London Hospitals NHS Foundation Trust. For services to Medicine. Robert John Williamson, DL. Chief Executive, The Community Foundation Tyne and Wear and Northumberland. For Voluntary and Charitable Services. Stephen John Willmer. Lately Deputy Head France, Security Policy and Operations, Ministry of Defence. For services to Defence and to International Relations. Dr.

Sources: en.wikipedia.org

Background from the literature

== Intragenic complementation == When multiple copies of a polypeptide encoded by a gene form a quaternary complex, this protein structure is referred to as a multimer. When a multimer is formed from polypeptides produced by two different mutant alleles of a particular gene, the mixed multimer may exhibit greater functional activity than the unmixed multimers formed by each of the mutants alone. In such a case, the phenomenon is referred to as intragenic complementation (also called inter-allelic complementation). Intragenic complementation appears to be common and has been studied in many different genes in a variety of organisms including the fungi Neurospora crassa, Saccharomyces cerevisiae and Schizosaccharomyces pombe; the bacterium Salmonella typhimurium; the virus bacteriophage T4, an RNA virus, and humans. The intermolecular forces likely responsible for self-recognition and multimer formation were discussed by Jehle.

These findings suggest specific parasite loci may be under vaccine-induced immune pressure and highlight potential targets for future optimization of whole-sporozoite vaccines. PfSPZ Vaccine development has been closely linked with malaria elimination efforts on Bioko Island, Equatorial Guinea. By 2024–2025, a series of registry studies, incidence surveys and dose-optimization trials had been completed as part of preparations for a large-scale, Africa-led phase 3 efficacy trial. These activities were coordinated through the Equatoguinean Malaria Vaccine Initiative, which aims to evaluate PfSPZ Vaccine in a setting with intense seasonal transmission and established malaria control programs.

=== Archaeological significance === Lindow Man marked the first discovery in Britain of a well-preserved bog body; its condition was comparable to that of Grauballe Man and Tollund Man from Denmark. Before Lindow Man was found, it was estimated that 41 bog bodies had been found in England and Wales and 15 in Scotland. Encouraged by the discovery of Lindow Man, a gazetteer was compiled, which revealed a far higher number of bog bodies: over 85 in England and Wales and over 36 in Scotland. Before the discovery of the bodies in Lindow Moss, British bog bodies had been a relatively neglected subject compared to European examples. The interest caused by Lindow Man led to more in-depth research of accounts of discoveries in bogs since the 17th century; by 1995, the numbers had changed to 106 in England and Wales and 34 in Scotland. The remains covered a large timeframe.

Robert Emmet Finnigan (May 27, 1927 – August 14, 2022) was an American pioneer in the development of gas chromatography–mass spectrometry equipment (GC/MS). Finnigan founded the Scientific Instruments Division of Electronic Associates, Inc., producing the first commercial quadrupole mass spectrometer in 1964. He then formed Finnigan Instruments Corporation to combine a computer system with a quadrupole mass spectrometer and gas chromatograph. Finnigan's GC/MS/computer systems are used to detect and identify trace organic compounds, making them important instruments for the monitoring and protection of the environment. They were adopted by the United States Environmental Protection Agency as a standard instrument for monitoring water quality and were fundamental to the work of the EPA.

Sources: en.wikipedia.org

Frequently asked questions